LEVEMIR FLEXPEN (insulin detemir) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2005.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
Levemir FlexPen is a long-acting basal insulin analog (insulin detemir) administered subcutaneously via prefilled pen device. It is indicated for diabetes management as a once- or twice-daily basal insulin to reduce hyperglycemia in patients with type 1 and type 2 diabetes. The drug works by mimicking endogenous insulin's glucose-lowering effects with a prolonged, peakless action profile suitable for basal insulin replacement.
Product is approaching loss of exclusivity with moderate market presence; commercial teams should expect resource reallocation toward newer pipeline assets and biosimilar defense strategies.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Worked on LEVEMIR FLEXPEN at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$1.0B Medicare spend — this is a commercially significant brand
Careers on Levemir FlexPen reflect a product in LOE transition: positions emphasize data analytics, supply chain optimization, and managed care strategy rather than traditional brand management or field sales growth. Working on this product offers exposure to biosimilar defense, payer negotiations, and complex healthcare economics—valuable expertise for senior commercial roles.
22 open roles linked to this drug